Hanall Biopharma Statistics

Total Valuation

KRX:009420 has a market cap or net worth of KRW 1.27 trillion. The enterprise value is 1.26 trillion.

Market Cap	1.27T
Enterprise Value	1.26T

Important Dates

The last earnings date was Tuesday, May 13, 2025.

Earnings Date	May 13, 2025
Ex-Dividend Date	n/a

Share Statistics

KRX:009420 has 50.74 million shares outstanding. The number of shares has decreased by -2.49% in one year.

Current Share Class	50.74M
Shares Outstanding	50.74M
Shares Change (YoY)	-2.49%
Shares Change (QoQ)	+2.23%
Owned by Insiders (%)	0.40%
Owned by Institutions (%)	18.05%
Float	34.42M

Valuation Ratios

PE Ratio	n/a
Forward PE	134.74
PS Ratio	9.03
PB Ratio	7.99
P/TBV Ratio	12.26
P/FCF Ratio	158.76
P/OCF Ratio	134.99
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-746.95
EV / Sales	8.95
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	157.27

Financial Position

The company has a current ratio of 2.66, with a Debt / Equity ratio of 0.01.

Current Ratio	2.66
Quick Ratio	1.08
Debt / Equity	0.01
Debt / EBITDA	0.55
Debt / FCF	0.20
Interest Coverage	-3.86

Financial Efficiency

Return on equity (ROE) is -1.00% and return on invested capital (ROIC) is -0.10%.

Return on Equity (ROE)	-1.00%
Return on Assets (ROA)	-0.08%
Return on Invested Capital (ROIC)	-0.10%
Return on Capital Employed (ROCE)	-0.17%
Revenue Per Employee	463.82M
Profits Per Employee	-5.56M
Employee Count	304
Asset Turnover	0.68
Inventory Turnover	1.86

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -24.40% in the last 52 weeks. The beta is 0.83, so KRX:009420's price volatility has been lower than the market average.

Beta (5Y)	0.83
52-Week Price Change	-24.40%
50-Day Moving Average	26,913.00
200-Day Moving Average	35,558.25
Relative Strength Index (RSI)	39.91
Average Volume (20 Days)	175,083

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KRX:009420 had revenue of KRW 141.00 billion and -1.69 billion in losses. Loss per share was -33.64.

Revenue	141.00B
Gross Profit	73.80B
Operating Income	-282.58M
Pretax Income	-552.76M
Net Income	-1.69B
EBITDA	2.94B
EBIT	-282.58M
Loss Per Share	-33.64

Full Income Statement

Balance Sheet

The company has 13.55 billion in cash and 1.61 billion in debt, giving a net cash position of 11.94 billion or 235.29 per share.

Cash & Cash Equivalents	13.55B
Total Debt	1.61B
Net Cash	11.94B
Net Cash Per Share	235.29
Equity (Book Value)	159.30B
Book Value Per Share	3,136.41
Working Capital	46.27B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 9.43 billion and capital expenditures -1.41 billion, giving a free cash flow of 8.02 billion.

Operating Cash Flow	9.43B
Capital Expenditures	-1.41B
Free Cash Flow	8.02B
FCF Per Share	158.10

Full Cash Flow Statement

Margins

Gross margin is 52.34%, with operating and profit margins of -0.20% and -1.20%.

Gross Margin	52.34%
Operating Margin	-0.20%
Pretax Margin	-0.39%
Profit Margin	-1.20%
EBITDA Margin	2.08%
EBIT Margin	-0.20%
FCF Margin	5.69%

Dividends & Yields

KRX:009420 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	2.49%
Shareholder Yield	n/a
Earnings Yield	-0.13%
FCF Yield	0.63%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on April 28, 2006. It was a forward split with a ratio of 10.

Last Split Date	Apr 28, 2006
Split Type	Forward
Split Ratio	10

Scores

KRX:009420 has an Altman Z-Score of 31.88.

Altman Z-Score	31.88
Piotroski F-Score	n/a